Workflow
益佰制药(600594) - 2019 Q1 - 季度财报

Financial Performance - Operating revenue fell by 14.44% to CNY 824,625,331.83 year-on-year[8] - Net profit attributable to shareholders decreased by 41.54% to CNY 59,230,798.23 compared to the same period last year[8] - Total operating revenue for Q1 2019 was CNY 824,625,331.83, a decrease of 14.5% compared to CNY 963,846,291.14 in Q1 2018[36] - Net profit for Q1 2019 was CNY 54,080,240.43, representing a decline of 49.1% from CNY 106,282,091.77 in Q1 2018[37] - The company reported a net profit attributable to shareholders of RMB 59,230,798.23, a decrease of 41.54% from RMB 101,322,017.16 in Q1 2018, mainly due to the disposal of Huainan Chaoyang Hospital Management Co., Ltd.[19] - The total comprehensive income for Q1 2019 was CNY 54,446,053.66, down from CNY 106,282,091.77 in Q1 2018[37] - The company reported a total comprehensive income of CNY 51.17 million for Q1 2019, compared to CNY 25.26 million in Q1 2018[40] Assets and Liabilities - Total assets decreased by 11.52% to CNY 5,729,391,531.10 compared to the end of the previous year[8] - The company's current assets totaled CNY 2,602,913,137.20, down from CNY 3,120,998,804.50, indicating a decrease of about 16.5%[27] - The total liabilities decreased to CNY 2,008,007,379.44 from CNY 2,517,632,614.13, a reduction of approximately 20.2%[29] - The company's equity attributable to shareholders increased to CNY 3,567,775,044.99 from CNY 3,503,440,804.42, showing an increase of about 1.8%[29] - The total liabilities decreased to CNY 1,922,014,013.55 in Q1 2019 from CNY 2,384,032,201.28 in Q1 2018[34] - Total liabilities amounted to CNY 2,517,632,614.13, with current liabilities at CNY 1,936,198,671.39 and non-current liabilities at CNY 581,433,942.74[48] Cash Flow - Net cash flow from operating activities improved to CNY 164,776,410.90, compared to a negative cash flow of CNY -154,209,766.34 in the previous year[8] - Operating cash flow net amount improved significantly to RMB 164,776,410.90 from a negative RMB 154,209,766.34 in Q1 2018, mainly due to the recovery of funds from matured notes[20] - In Q1 2019, the company generated a net cash flow from operating activities of ¥108,025,688.15, a significant improvement compared to a net outflow of ¥167,399,476.33 in Q1 2018[44] - The company reported a net cash flow from financing activities of -¥108,528,566.81, down from a positive cash flow of ¥84,939,687.55 in Q1 2018[44] Investments and Expenses - R&D expenses increased by 74.34% to RMB 19,901,601.62 compared to RMB 11,415,576.32 in Q1 2018, primarily due to increased investment in R&D projects[17] - Research and development expenses rose to CNY 19,901,601.62 in Q1 2019, up from CNY 11,415,576.32 in Q1 2018, indicating a focus on innovation[36] - The company incurred sales expenses of CNY 226.25 million, down 18.9% from CNY 278.84 million in the previous year[39] - The company reported a significant decrease in financial expenses by 97.17% to RMB 612,384.28 from RMB 21,602,721.12, due to reclassification of government subsidies[17] Shareholder Information - The number of shareholders reached 61,746 at the end of the reporting period[12] - Earnings per share for Q1 2019 was CNY 0.075, down from CNY 0.128 in Q1 2018[37] Equity and Borrowings - Long-term borrowings increased by 100.56% to RMB 37,936,687.22 from RMB 18,915,825.40, primarily due to the repayment of long-term loans in the previous period[19] - The company maintained long-term borrowings at CNY 10,000,000.00, unchanged from the previous year[34] - The company provided a guarantee for a loan application of RMB 336 million for its subsidiary, Hainan Chang'an International Pharmaceutical Co., Ltd.[23]